Literature DB >> 33731774

Role of the mTOR-autophagy-ER stress pathway in high fructose-induced metabolic-associated fatty liver disease.

Ya-Lin Wang1, Xiu Zhou1,2, Dong-Li Li1, Ji-Ming Ye3,4.   

Abstract

Metabolic-associated fatty liver disease (MAFLD) is the most common metabolic disease with a global prevalence of 25%. While MAFLD is serious and incurable at the later stage, it can be controlled or reversed at the early stage of hepatosteatosis originating from unhealthy diets. Recent laboratory evidence implicates a critical role of the mammalian target of rapamycin (mTOR)-autophagy signaling pathway in the pathogenesis of MAFLD induced by a high-fructose diet mimicking the overconsumption of sugar in humans. This review discusses the possible molecular mechanisms of mTOR-autophagy-endoplasmic reticulum (ER) stress in MAFLD. Based on careful analysis of recent studies, we suggest possible new therapeutic concepts or targets that can be explored for the discovery of new anti-MAFLD drugs.
© 2021. The Author(s), under exclusive licence to CPS and SIMM.

Entities:  

Keywords:  ER stress; MAFLD; autophagy; high-fructose diet; mTOR; metabolic syndrome

Mesh:

Substances:

Year:  2021        PMID: 33731774      PMCID: PMC8724298          DOI: 10.1038/s41401-021-00629-0

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN: 1671-4083            Impact factor:   6.150


  58 in total

1.  Emerging Pharmacological Targets for the Treatment of Nonalcoholic Fatty Liver Disease, Insulin Resistance, and Type 2 Diabetes.

Authors:  Leigh Goedeke; Rachel J Perry; Gerald I Shulman
Journal:  Annu Rev Pharmacol Toxicol       Date:  2019-01-06       Impact factor: 13.820

Review 2.  Repurposing Drugs to Target the Diabetes Epidemic.

Authors:  Nigel Turner; Xiao-Yi Zeng; Brenna Osborne; Suzanne Rogers; Ji-Ming Ye
Journal:  Trends Pharmacol Sci       Date:  2016-02-18       Impact factor: 14.819

Review 3.  MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease.

Authors:  Mohammed Eslam; Arun J Sanyal; Jacob George
Journal:  Gastroenterology       Date:  2020-02-08       Impact factor: 22.682

Review 4.  Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis.

Authors:  Zobair Younossi; Frank Tacke; Marco Arrese; Barjesh Chander Sharma; Ibrahim Mostafa; Elisabetta Bugianesi; Vincent Wai-Sun Wong; Yusuf Yilmaz; Jacob George; Jiangao Fan; Miriam B Vos
Journal:  Hepatology       Date:  2019-06       Impact factor: 17.425

Review 5.  Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention.

Authors:  Zobair Younossi; Quentin M Anstee; Milena Marietti; Timothy Hardy; Linda Henry; Mohammed Eslam; Jacob George; Elisabetta Bugianesi
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-09-20       Impact factor: 46.802

Review 6.  Treatment of NAFLD with diet, physical activity and exercise.

Authors:  Manuel Romero-Gómez; Shira Zelber-Sagi; Michael Trenell
Journal:  J Hepatol       Date:  2017-05-23       Impact factor: 25.083

Review 7.  Nonalcoholic Fatty Liver Disease 2020: The State of the Disease.

Authors:  Thomas G Cotter; Mary Rinella
Journal:  Gastroenterology       Date:  2020-02-13       Impact factor: 22.682

Review 8.  Epidemiological Features of NAFLD From 1999 to 2018 in China.

Authors:  Jianghua Zhou; Feng Zhou; Wenxin Wang; Xiao-Jing Zhang; Yan-Xiao Ji; Peng Zhang; Zhi-Gang She; Lihua Zhu; Jingjing Cai; Hongliang Li
Journal:  Hepatology       Date:  2020-05       Impact factor: 17.425

Review 9.  Recommendations for Diagnosis, Referral for Liver Biopsy, and Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis.

Authors:  Erin K Spengler; Rohit Loomba
Journal:  Mayo Clin Proc       Date:  2015-07-26       Impact factor: 7.616

10.  Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity.

Authors:  K G M M Alberti; Robert H Eckel; Scott M Grundy; Paul Z Zimmet; James I Cleeman; Karen A Donato; Jean-Charles Fruchart; W Philip T James; Catherine M Loria; Sidney C Smith
Journal:  Circulation       Date:  2009-10-05       Impact factor: 29.690

View more
  2 in total

1.  Luteolin alleviates cognitive impairment in Alzheimer's disease mouse model via inhibiting endoplasmic reticulum stress-dependent neuroinflammation.

Authors:  Jie-Jian Kou; Jun-Zhuo Shi; Yang-Yang He; Jiao-Jiao Hao; Hai-Yu Zhang; Dong-Mei Luo; Jun-Ke Song; Yi Yan; Xin-Mei Xie; Guan-Hua Du; Xiao-Bin Pang
Journal:  Acta Pharmacol Sin       Date:  2021-07-15       Impact factor: 6.150

2.  Cryptotanshinone Inhibits the Growth of HCT116 Colorectal Cancer Cells Through Endoplasmic Reticulum Stress-Mediated Autophagy.

Authors:  Xiaojing Fu; Wenwen Zhao; Kangkang Li; Jingyi Zhou; Xuehong Chen
Journal:  Front Pharmacol       Date:  2021-06-17       Impact factor: 5.810

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.